Naglazyme (Galsulfase)

Galsulfase is a recombinant form of the human N‑acetylgalactosamine‑4‑sulfatase enzyme. After intravenous infusion, it is taken up by cells and directed to lysosomes, where it cleaves sulfate groups from dermatan sulfate and chondroitin‑4‑sulfate, thereby decreasing their accumulation and improving cellular function.

The dose of Naglazyme is individualized. A qualified prescriber determines the amount and infusion schedule based on the patient’s body weight, disease severity, and clinical response. Dosing regimens are adjusted over time according to laboratory and clinical monitoring.

Safety data for Naglazyme in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with a specialist and careful risk‑benefit assessment are essential.

To order Naglazyme, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, cold‑chain shipping details, and required import documentation.

Naglazyme is the only approved enzyme replacement therapy specifically for MPS VI. Alternative approaches, such as supportive care or hematopoietic stem‑cell transplantation, address symptoms but do not replace the deficient enzyme. Compared with supportive care, Naglazyme directly targets the underlying biochemical defect, offering disease‑modifying potential.

Naglazyme must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product must be transported, maintain the cold chain using validated insulated containers and temperature monitors.

Naglazyme is given as an intravenous infusion. The solution for injection is reconstituted according to the manufacturer’s instructions and administered by a qualified healthcare professional in a clinical setting. Infusion times and rates are determined by the prescribing physician and may be adjusted based on patient tolerance.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, serum‑sickness‑like illness, significant liver enzyme elevations, and rare hematologic abnormalities like thrombocytopenia. Patients should be monitored closely during and after infusion for any signs of these reactions.

Naglazyme should not be used in individuals with a known hypersensitivity to galsulfase or any of its excipients. Caution is also advised for patients with severe liver disease or uncontrolled cardiac or pulmonary conditions, as these may increase the risk of serious adverse events.